Frugal Coronary Angioplasty, Still an Option after 30 Years
IAGS (International Andreas Gruentzig Society) Proceedings:
Frugal Coronary Angioplasty, Still an Option after 30 Years
- Bernhard Meier, MD
| |
|  | | Table 2. World experience with percutaneous coronary intervention
as of August 1980 (818 cases total).* |
|  | | Table 1. History of interventional cardiology.
|
Coronary angioplasty was not the first interventional procedure in cardiology (Table 1), but it clearly launched the discipline called interventional cardiology as we know it today. Percutaneous coronary intervention (PCI), as it is customarily called today, had a slow start. Three years into its existence, the world experience still totaled less than 1,000 interventions (Table 2). Andreas Grüntzig showed impressively and unmistakably that PCI could be applied in a successful and safe manner even before the development of stents. The first case showing a good result up to the current day (Figure 1) may be considered anecdotal. However, Andreas Grüntzig’s lifetime series, cut short by his demise 5 months before the first coronary stent implantation, 1 confirms it unequivocally. He and his close collaborators performed more than 2,000 balloon-only procedures without any in-hospital mortality (Table 3).
|  | | Table 3. Percutaneous coronary intervention results of Andreas
Grüntzig and his intimate collaborators from Case 1 (September 16,
1977) to his death (October 25, 1985). Courtesy of Gary Roubin, MD. |
|  | | Figure 1. (A) Stenosis in the left anterior descending artery of the world’s first patient to undergo percutaneous coronary intervention by Andreas
Grüntzig in Zürich on September 16, 1977, when the patient and his doctor were both 38 years of age (arrow). |
PCI has seen lots of adjunctive therapies and even so-called balloon replacement therapies over the past 30 years. Few have prevailed, and even today, what is really important boils down to 5 components: state-of-the-art balloons, guidewires, guiding catheters, X-ray equipment, and stents. Add to these novel antiplatelet agents and perhaps percutaneous left ventricular assist devices that save an occasional life in large-volume centers (Table 4). Techniques to close the femoral puncture site are important comfort items for both physician and patient. All of the other presumable assets were either useless (some even dangerous) or remain completely optional. Nonetheless, many of them have made it into routine use in most catheterization laboratories. Even the coronary stent is clearly overused these days. First it went through a difficult initial phase where its 20% thrombosis rate was not sufficiently corrected for the situations in which the stents were used (bailout for impending or established abrupt closure), but rather compared with the 7% thrombosis rate of plain balloon angioplasty. This bane vanished when stents were implanted mostly in elective cases. Erroneously, the drastically decreasing stent thrombosis rate was not initially attributed (as it should have been) to the transition from bailout to elective stenting, but rather to changes in implantation techniques (higher pressures) and the addition of a second antiplatelet agent (thienopyridine). The latter contributed to improvement in stenting results, but only to a minor degree.
|  | | Table 5. Devices and techniques used in the case described.
|
|  | | Table 4. Percutaneous coronary interventional devices and techniques
1977–2008 |
The community of angioplasty operators then went to the other extreme and made stenting the default procedure, turning a completely blind eye on the fact that without stents, at least 70% of lesions never had a problem, neither acutely nor during follow up. In these 70% of patients (who of course never ceased to exist), a stent cannot be of any benefit, but it can harm during the “unnecessary” implantation, or it can harm during follow up by creating in-stent restenosis that is much more difficult to treat than restenosis after plain balloon angioplasty or by late thrombosis, unseen after balloon angioplasty. As soon as default stenting was ubiquitously adopted, the initial advantage of stenting in terms of survival and avoidance of myocardial infarctions due to abrupt vessel closure was lost again during mid-term follow up. The advent of drug-eluting stents basically eliminated the problem of in-stent restenosis. Strangely, when for a while their safety was questioned, people considered a fallback to bare-metal stents, but not to plain balloon angioplasty, though only the latter completely precludes late thrombosis.
|  | | (C) Exercise bicycle stress test shortly after the 30-year anniversary of the intervention
showing a normal electrocardiogram (apart from a preexisting right bundle-branch block) at peak exercise of 167 Watt with a peak heart rate of 149
beats per minute and a peak blood pressure of 270/120 mmHg (courtesy of Paul Dubach, MD). |
|  | | (B) Last available follow-up
angiogram 23 years later with an excellent result (arrow). |
|  | | Figure 1. (A) Stenosis in the left anterior descending artery of the world’s first patient to undergo percutaneous coronary intervention by Andreas
Grüntzig in Zürich on September 16, 1977, when the patient and his doctor were both 38 years of age (arrow). |
A temporary setback of PCI is currently witnessed in light of the falsely-accused drug-eluting stent and the falsely-interpreted comparisons between PCI and conservative treatment in the Mass II,2 PET and COURAGE trials.4 These trials found no difference in survival or instances of myocardial infarctions in stable coronary patients treated with either PCI (i.e., bare-metal stenting) or medical therapy plus PCI only when symptoms did not abate. The interpretation that this meant PCI was not warranted cannot be condoned. In contrast, the trials should be interpreted such that in spite of having repaired the problem in the group that underwent PCI, the mid-term outcomes were not worse, although the PCI-arm patients already had all the possible problems from the intervention behind them, whereas the conservative group still had them ahead of them. In other words, if you know your brakes need fixing, you may well drive on for a certain time without fixing them. The fact that you did not have an accident does not mean that your brakes never needed fixing. These storms in a teacup could, however, have called us back to reason that, yes, we should do the interventions but, no, we should not fall victim to the temptation of overdoing things. The case in Figure 2 shows that interventional cardiology can do complex things with rather frugal techniques and materials.5 Table 5 is a summary of procedures conducted in this patient and the material used. The patient was released 3 days postprocedure.
|  | | Figure 2. A 53-year-old office worker experienced unrelenting chest pain that began 3 hours prior to emergency cardiac catheterization while
trimming a tree, crouched on a ladder. His only risk factor was smoking and he presented with inferior ST-segment elevation. A 5 Fr Amplatz left
AL-2 guiding catheter was inserted without nicking the skin or an introducer sheath (Figure 2 continues on next page).A) This catheter was first used for an injection into the left ventricle
shown in a left anterior oblique projection. There was akinesia of a
territory best associated with a posterolateral branch of a dominant
right coronary artery. |
|  | | (B) The catheter was then placed into the left coronary artery that was
assumed to be the nonculprit vessel. Surprisingly, a subtotal stenosis of
a large anterolateral marginal branch was found (arrow). This clearly
did not fit with the hypokinesia and was thought to be an additional
problem unrelated to the infarction.
|
|  | | Figure 2 (continued). (C) The AL-2 catheter was then flipped
across to the right coronary artery. There, the culprit lesion was
found in the form of a fairly long thrombus saddling the crux of the
dominant right coronary artery (arrows). In addition, the posterolateral
branch was cut off more distally (arrow head). While there
was atherosclerotic disease of the right coronary artery, this clearly
looked like a thrombotic occlusion with a large embolus, most probably
not originating from the coronary artery itself. An infusion
with abciximab was started after an intravenous bolus injection.
| |
References 1. Puel J, Lacapere B, Sabathier M, et al. Coronary revascularization at the acute phase of myocardial infarction. Short and median-term survival of 359 patients. Multicenter study. Arch Mal Coeur Vaiss 1986;79:409–417. 2. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): A randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: One-year results. J Am Coll Cardiol 2004;43:1743–1751. 3. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: A randomized trial. Circulation 2004;109:1371–1378. 4. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–1516. 5. Meier B. Frugal coronary angioplasty. In: Meier B (Ed). Interventional Cardiology: An Atlas of Investigation and Therapy. Oxford, United Kingdom: Clinical Publishing. 2004, pp. 21–43. |
| The Journal of Invasive Cardiology - ISSN: 1042-3931 - Volume 20 - Issue 4 - April 2008 - Pages: - | |
|
Create a Successful Vena Cava Filter Practice
Accredited CD
This activity is supported by an educational grant from Cook Incorporated and has been designed for Interventional Cardiologists, Vascular Surgeons, Fellows and Interventional Cardiovascular Nurses and Technologists.
|
| |
|
|
|
|
Achieving Optimal Outcomes in Carotid Stenting: Lessons Learned from Recent Clinical Trials
Complimentary Accredited ON DEMAND Webcast
Topics
1. EVA-3S & Space-Bumps in the road
2. CAPTURE 3500-Lesion morphology & Predictors for Stroke
3. CAPTURE II vs. EXACT 1500-Does open or Closed Cell Stent design really matter?
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Neurologists, Interventional Nurses and Technologists with an interest in the diagnosis and treatment of peripheral artery disease. |
|
Anticoagulation Techniques for Peripheral Vascular Interventions
Complimentary Accredited ON DEMAND Webcast
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Podiatric Physicians, Endovascular Allied Professionals, Endocrinologists, Wound Care Specialists, Directors of the Wound Care Clinic, and Primary Care Physicians, Pharmacists, Nurses and Technologists.
|
|
|
|
|
|
March 2007 Supplement
|
On-Demand Webcast
|
Archived Webcast
|
|
|
|
|
|
About HMP Communications
HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications |
© 2008 HMP Communications | All Rights Reserved
83 General Warren Blvd, Suite 100 | Malvern, PA 19355 | 800.237.7285
|
|
| | |